

# UCSF

## UC San Francisco Previously Published Works

### Title

Clinical and ultrastructural spectrum of diffuse lung disease associated with surfactant protein C mutations

### Permalink

<https://escholarship.org/uc/item/0v18j477>

### Journal

European Journal of Human Genetics, 23(8)

### ISSN

1018-4813

### Authors

Peca, D  
Boldrini, R  
Johansson, J  
[et al.](#)

### Publication Date

2015-08-21

### DOI

10.1038/ejhg.2015.45

Peer reviewed

# Clinical and ultrastructural spectrum of diffuse lung disease associated with surfactant protein C mutations

Donatella Peca<sup>1</sup>, Renata Boldrini<sup>2</sup>, Janne Johannson<sup>3</sup>, Joseph T Shieh<sup>4</sup>, Arianna Citti<sup>2</sup>, Stefania Petrini<sup>1</sup>, Teresa Salerno<sup>5</sup>, Salvatore Cazzato<sup>6</sup>, Raffaele Testa<sup>7</sup>, Francesco Messina<sup>8</sup>, Alfredo Onofri<sup>9</sup>, Giovanna Cenacchi<sup>10</sup>, Per Westermark<sup>11</sup>, Nicola Ullman<sup>5</sup>, Paola Cogo,<sup>12</sup> Renato Cutrera<sup>5</sup> and Olivier Danhaive<sup>4,13</sup>.

## Corresponding author:

Olivier Danhaive, M.D.

Department of Pediatrics, University of California San Francisco

San Francisco General Hospital

1001 Potrero Avenue, Mailstop 6E, San Francisco, CA 94110

Telephone: +1-415-206-8361 - Fax: +1-415-206-3686

Email: [danhaiveo@peds.ucsf.edu](mailto:danhaiveo@peds.ucsf.edu)

## Running title:

Histopathology and ultrastructure in SP-C mutants

## Authors affiliations:

<sup>1</sup>Research core laboratories, Bambino Gesù Children's Hospital, Rome, Italy;

<sup>2</sup>Division of Anatomopathology, Bambino Gesù Children's Hospital, Rome, Italy;

<sup>3</sup>Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Huddinge, Sweden;

<sup>4</sup>Department of Pediatrics, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA;

<sup>5</sup>Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy;

<sup>6</sup>Division of Pediatric Pulmonology, S. Orsola-Malpighi University Hospital, Bologna, Italy;

<sup>7</sup>Division of Pediatric intensive Care, Santobono Hospital, Naples, Italy;

<sup>8</sup>Division of Neonatology, Villa Betania Hospital, Naples, Italy;

<sup>9</sup>Division of Pediatric Intensive Care, Bambino Gesù Children's Hospital, Rome, Italy;

<sup>10</sup>Division of Clinical Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy;

<sup>11</sup>Department of Immunology, Genetics and Pathology, Uppsala University, Sweden;

<sup>12</sup>Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy;

<sup>13</sup>Department of Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, Rome, Italy.

1 Abstract

2 Genetic defects of surfactant metabolism are associated with a broad range of clinical  
3 manifestations, from neonatal respiratory distress syndrome to adult interstitial lung  
4 disease. Early therapies may improve symptoms but diagnosis is often delayed due to  
5 phenotype and genotype variability. Our objective was to characterize the  
6 cellular/ultrastructural correlates of surfactant protein-C mutations in children with  
7 idiopathic diffuse lung diseases. We sequenced *SFTPC* -the gene encoding surfactant protein  
8 C-, *SFTPB* and *ABCA3*, and analyzed morphology, ultrastructure and surfactant protein  
9 expression in lung tissue when available. We identified eight subjects who were  
10 heterozygous for SP-C mutations. Median age at onset and clinical course was variable.  
11 None of the mutations were located in the mature peptide-encoding region, but were either  
12 in the pro-protein BRICHOS or linker C-terminal domains. While lung morphology was  
13 similar to other genetic surfactant metabolism disorders, electron microscopy studies  
14 showed specific anomalies suggesting surfactant homeostasis disruption, plus trafficking  
15 defects in the four subjects with linker domain mutation and protein misfolding in the  
16 single BRICHOS mutation carrier in whom material was available. Immunolabeling studies  
17 showed increased proSP-C staining in all cases. In two cases, amyloid deposits could be  
18 identified. Immunocytochemistry and ultrastructural studies may be useful for diagnostic  
19 purposes and for genotype interpretation.

20

21 Keywords: Surfactant protein C, diffuse parenchymal lung disease, mutation, lamellar  
22 bodies, amyloid, BRICHOS domain.

## 1 Background

2 Pediatric diffuse parenchymal lung diseases (pDLD) are rare disorders with various  
3 etiologies, characterized by chronic or progressive gas exchange impairment and multifocal  
4 or diffuse infiltrates. Mutations in several surfactant-related genes have been increasingly  
5 recognized as causes of pDLD <sup>1</sup>; these genes encode different types of protein: intrinsic  
6 surfactant peptides (surfactant protein B [SP-B] and C [SP-C] <sup>2</sup>), transmembrane  
7 transporters (ATP-binding cassette protein A3 [ABCA3] <sup>3</sup>), gene expression regulators -  
8 thyroid transcription factor 1 [TTF-1]), receptors -granulocyte macrophage colony  
9 stimulating factor receptor subunits a and b [CSF2R $\alpha$  and CSF2R $\beta$ ]), accounting in part for  
10 the extreme diversity of the clinical spectrum. SP-C is a small hydrophobic peptide, which,  
11 in association with SP-B, plays a key role in surface film formation and stability at the  
12 alveolar gas-liquid interface <sup>4</sup>. The *SP-C* gene, also designated *SFTPC*, is located at the 8p21  
13 locus, spanning 3.5 kb, is composed of 6 exons, and encodes a 191 or 197 aminoacid (aa)  
14 apoprotein depending upon alternative splicing, that subsequently traffics through the  
15 endoplasmic reticulum and the Golgi and undergoes cleavage of N- and C-terminus residues  
16 in multivesicular bodies (MVBs), leading to formation of the 35 aa mature SP-C peptide <sup>5</sup>.  
17 This peptide interacts with SP-B and phospholipids inside the lamellar bodies (LBs) to form  
18 bioactive surfactant. The N-terminus domain is involved in cell trafficking and the C-  
19 terminus domain harbors the BRICHOS domain, a chaperone preventing aggregation of the  
20 hydrophobic mature peptide during post-transcriptional processes. SP-B and ABCA3  
21 deficiencies are autosomal recessive diseases presenting as neonatal respiratory distress  
22 syndrome (RDS) typically fatal within the first months of age (although certain ABCA3  
23 mutations may lead to later onset disease <sup>6</sup>). SP-C mutations are mostly mono-allelic, either  
24 sporadic or inherited and are expressed in a dominant fashion in about 50% of cases.

1 Clinical onset varies from birth to advanced adulthood, with variable severity and outcome <sup>7</sup>.  
2 Complex molecular mechanisms account in part for the phenotypic diversity of the disease.  
3 Environmental factors also play a key role in modulating the disease course, as carriers of  
4 the same mutation in a single pedigree may show a broad variability of onset and  
5 presentation <sup>8,9</sup>. Lung infections often trigger or complicate the course of pDLD in SP-C  
6 mutation carriers, especially in infantile age. In the context of an ongoing research project  
7 aimed at determining the contribution of rare and common variants of surfactant-related  
8 genes in pDLD, we report the clinical features and molecular and histological findings in  
9 eight subjects heterozygous for *SFTPC* rare variants.

10

## 11 Methods

12 **Subjects.** From 2005 to 2012, infants and children with a history of unexplained persistent  
13 or progressive diffuse lung disease based on clinical signs (abnormal auscultation, cough,  
14 dyspnea, hypoxemia) with an onset between birth and 18 years plus evidence of diffuse  
15 parenchymal lung disease were referred to our center for genetic testing. Exclusion criteria  
16 consisted of acute/chronic airway infections, cystic fibrosis, aspiration pneumonia, immune  
17 deficiencies, primary ciliary dyskinesia, tuberculosis and allergic bronchopulmonary  
18 aspergillosis. Parental consent was obtained when applicable. We sequenced *SFTPC*, *SFTPB*  
19 and *ABCA3*, plus other genes in selected cases based on family history and clinical findings  
20 (online supplement). Patient #7 was referred to our center as a young adult, but was  
21 included in this series as she had respiratory symptoms since one year of age. The study  
22 was conducted in compliance with the hospital internal review board and research ethics  
23 committee.

24

1 **DNA analysis.** We performed PCR-based mutation analysis of the *SFTPC*, *SFTPB* and *ABCA3*  
2 genes by Sanger's technique. All coding exons were amplified by PCR with primers  
3 synthesized for the coding and flanking regions of each gene using the human genome  
4 sequences ENSG00000168484 (*SFTPC*), ENSG00000168878 (*SFTPB*) and  
5 ENSG00000167972 (*ABCA3*), and were sequenced bidirectionally <sup>10</sup>. Amino acid sequences  
6 were expressed following the NCBI NP\_001165881 (proSP-C) and NP\_001080.2 (*ABCA3*)  
7 reference sequences. Familial DNA was sequenced when available, and rare variants were  
8 tested in 100 alleles and in the 1000 Genomes Project phase1 NHBLI Exome sequencing  
9 project (1000G) and NHLBI Grand Opportunity Exome Sequencing Project (ESP) databases.  
10 The impact of predicted amino-acid changes on protein structure and function was assessed  
11 by SIFT <sup>11</sup> and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>). Aa conservation was  
12 assessed by sequence comparison in 28 vertebrate species. The *SFTPC* variants were  
13 submitted to the Leiden Open Variation Database (LOVD) public database  
14 (<http://www.lovd.nl>); identification numbers are provided in table 2. For previously  
15 described variants, we also provided the identification number in the dbSNP public  
16 database when available.

17  
18 **Optical microscopy.** Sections of formaldehyde-fixed paraffin-embedded lung tissue were  
19 labeled with 1:100 mouse anti SP-B antibody (Lab Vision, Fremont, CA) or 1:400 polyclonal  
20 rabbit anti proSP-C (Millipore, Temecula, CA) <sup>12</sup> and detected with peroxidase-coupled  
21 secondary antibodies (Dako, Glostrup, Denmark) after staining with hematoxylin-eosin;  
22 normal lung samples were obtained from 3 age-matched subjects (3, 12 and 18 month-old)  
23 deceased from a non-pulmonary cause. Lung tissue was analyzed for amyloid by polarized  
24 light optical microscopy after Congo Red staining <sup>13</sup>. When frozen tissue was available, we

1 performed confocal fluorescence microscopy after dual immunolabeling with proSP-C, an  
2 endoplasmic reticulum (ER) marker (PDI) and a LB and lysosome marker (LAMP3) (see  
3 online supplement).

4  
5 **Transmission electron microscopy.** Samples from cases #1-3 and 6 were obtained at the  
6 main institution following similar procedures, fixed in Karnovsky's fixative, postfixed in 1 %  
7 OsO<sub>4</sub> and embedded in EMbed-812. Ultrathin sections stained with uranyl acetate and lead  
8 citrate were examined with a Zeiss EM CENTRA 100 microscope (Carl Zeiss, Oberkochen,  
9 Germany). Case #6 was obtained in another institution and processed differently: fresh  
10 bronchoalveolar lavage (BAL) samples were centrifuged at 800 RPM; cell pellets were  
11 resuspended in 2,5% glutaraldehyde in 0,1 M cacodylate buffer, postfixed in 1 % OsO<sub>4</sub>,  
12 dehydrated in graded ethanol and embedded in araldite. Ultrathin sections stained with  
13 uranyl acetate and lead citrate were examined with a Philips 410 microscope (Philips,  
14 Eindhoven, the Netherlands).

15

## 16 Results

17 **Clinical features (table 1).** All infants were Caucasian and of Italian origin except patient  
18 #4, who was of Romanian origin. They were born at term except patient #8 at 28 weeks of  
19 gestation, all with birth weight appropriate for gestational age (median 3,01 Kg; range 0.90-  
20 3.70), Four were males and four females. One had a family history of a sibling with fatal lung  
21 disease at 16 months. Median age at onset was 5.5 months (range 0-12). All except patient  
22 #8 showed significant postnatal failure to thrive. One infant (case #8) was a 28-week  
23 preterm triplet who presented with unexpectedly severe RDS compared to the two siblings,  
24 requiring multiple surfactant administrations, mechanical ventilation until 32 weeks, and

1 supplemental oxygen until 1 month corrected gestational age, whereas the other two  
2 siblings were only on CPAP for less than 3 weeks. The proband's subsequent course was  
3 normal, with a follow-up of 15 months. The other seven cases were asymptomatic in early  
4 infancy and presented with respiratory symptoms from 1-12 months, five of which after  
5 viral bronchiolitis. Lung high resolution computed tomography (HRCT) performed at a  
6 median age of 9 months (except case #7) showed ground glass opacities plus a combination  
7 of small and large cysts, subpleural nodules, lobar emphysema, air leaks and/or focal  
8 infiltrates. Case #7's prominent feature was multiple bronchiectasis <sup>14</sup>. Two infants died, at  
9 6 and 8 months respectively; among survivors, two were on home oxygen therapy at 25 and  
10 48 months with one enlisted for lung transplant, two were on room air with recurrent  
11 exacerbations requiring oxygen supplementation, and two were stable with no symptoms.

12  
13 **Molecular genetics.** Of the 88 subjects of the cohort, eight harbored an *SFTPC* rare coding  
14 variant (table 2); in four (#2, 4, 5 and 6) the mutation was inherited from one parent, who  
15 was asymptomatic. Patient #1 carried the p.(Glu66Lys) mutation, previously reported to  
16 cause neonatal respiratory failure <sup>15</sup>; in addition, we found the unreported ABCA3  
17 synonymous c.1383 G>A coding variant (p.(Val461=), LOVD:0000055959) of unclear  
18 clinical significance. Cases #2-5 carried the p.(Ile73Thr) mutation, the most frequently  
19 reported with a broad spectrum of manifestations from neonatal RDS to adult ILD <sup>7,8,16-23</sup>.  
20 Patient #6 carried the c.304G>A variation leading to the p.(Val102Met) aa change,  
21 previously reported without clinical description <sup>13</sup>. In patient #7, the c.463G>C variation  
22 was identified in exon 5, causing the p.(Ala155Pro) aa change, previously published as a  
23 case report <sup>14</sup>. Patient #8 carried the previously unreported c.518C>A variation leading to  
24 the p.(Pro173His) aa change. The new variants reported here were not present in 100



1 control alleles, and were neither found in 1000G nor in ESP except for patient #7 (c.463G>C  
2 variant, MAF 0.0359).

3  
4 **Anatomopathology.** The four cases in whom a lung biopsy was performed (#1-3 and 6)  
5 showed a similar pattern of SP-B -positive alveolar epithelial type-II cells hyperplasia,  
6 alveolar spaces filled with SP-B -positive desquamated epithelial cells and alveolar  
7 macrophages, and interstitial thickening with fibroblast proliferation, corresponding to  
8 desquamative interstitial pneumonia (or pulmonary alveolar proteinosis in older literature).

9  
10 **Immunohistochemistry.** In controls, immunostaining for proSP-C showed a focal  
11 cytoplasmic expression adjacent to LBs, which appear as clearer, outlined vesicles at the  
12 apical pole <sup>9</sup>. In subjects with linker domain mutations (cases #1, #2 and #3), there was  
13 increased staining for ProSP-C, which appeared to be localized largely to cytoplasmic  
14 vesicles similar to those identified by others as endosomes in the same p.(Glu66Lys)  
15 mutation <sup>15</sup>. In the BRICHOS mutant (case #6), there was also markedly increased proSP-C  
16 staining with some denser staining lining the nucleus, similar to the misfolded protein  
17 response pattern described in a  $\Delta$ exon4 (BRICHOS) mutagenesis experiment <sup>24</sup> (Figure 1).

18  
19 **Dual channel immunofluorescence.** In the patient carrying the linker domain  
20 p.(Glu66Lys) mutation (case #1), confocal microscopy with co-labeling of SP-B and proSP-C  
21 showed a much stronger signal than SP-B compared to control, suggesting proSP-C  
22 overexpression (not shown). ProSP-C was only limitedly co-expressed with DPI in the  
23 p.(Glu66Lys) mutant as well as in the control lungs. However, the mutant showed a stronger

1 co-expression of proSP-C with LAMP3 than the control, with a pattern of large cytoplasmic  
2 vesicles (Figure S1, online supplement).

3  
4 **Polarized light microscopy.** In cases #1 and 6 (Figure 2), small amyloid deposits with  
5 typical staining properties were identified in the interstitium, in association with  
6 macrophages, not found in lung tissue from control subjects. We attempted immunolabeling  
7 experiments with antibodies specifically targeted to the C-terminal propeptide and to the  
8 BRICHOS domain, but the small size of amyloid deposits precluded identification of  
9 immunoreactive material (not shown).

10  
11 **Transmission electron microscopy (figure 3).** Compared to control, Cases #1, #2 and #3  
12 (linker domain mutants) showed numerous , large organelles containing amorphous  
13 material and scarce electron-dense phospholipid structures likely corresponding to early  
14 endosomes <sup>25</sup>. Only a few MVBs and immature LBs with altered pseudomyelin structure  
15 could be observed in these subjects, the content of which is secreted in the alveolar lumen  
16 (case #1, figure S2, online supplement), suggesting a profound disruption of surfactant  
17 homeostasis. A similar pattern could be observed in an AEC2 isolated from bronchoalveolar  
18 lavage in patient #5, also a linker domain mutant. In contrast, patient #6 (BRICHOS mutant)  
19 showed a hyperplastic ER compared to control, perinuclear electron-dense cytoplasmic  
20 aggregates, abundant lysosomes, and some MVBs and immature LBs showing pseudomyelin  
21 structures, albeit less than in control.

22

## 23 Discussion

24 SP-C mutations are a significant and probably underestimated cause of diffuse lung disease

1 at various ages. Prevalence in pDLD series, as in ours, varies from 8 to 17%<sup>1,3,6,7,19,26</sup>. SP-C  
2 mutations have been described in term<sup>15,27</sup> or late preterm infants with severe RDS,  
3 although this presentation is more typical of SP-B and ABCA3 bi-allelic mutations<sup>2</sup>. The  
4 typical presentation of SP-C defects consists of dyspnea, cough or wheezing with an onset  
5 between 2 and 12 months of age, gradual cyanosis and failure to thrive<sup>8,20,23,28</sup>. In this paper  
6 the youngest subject, a 28-week preterm triplet carrying the p.(Pro173His) mutation was  
7 identified by comparing RDS severity with his two siblings with wild-type SP-C alleles.  
8 Conversely, in the literature, SP-C mutations have been found in adults with familial  
9 idiopathic pulmonary fibrosis<sup>29</sup> and in adults 14 to 68 year-old in one pedigree<sup>30</sup>,  
10 suggesting that environmental factors or individual genetic background are significant  
11 determinants.

12  
13 Steroids, hydroxychloroquine and azithromycin are commonly used in SP-C-related pDLD.  
14 Azithromycin has anti-amyloid properties<sup>35</sup>, and hydroxychloroquine affects intracellular  
15 proSP-C processing<sup>36</sup>; hence these drugs may possibly have selective effects on specific  
16 mutations, although there are currently no clinical data available to support this concept. All  
17 of our subjects received one or more of these interventions at various points in their disease  
18 course, some before the biopsy was obtained, so it is difficult to know if these treatments  
19 modified the histologic or ultrastructural appearance in any fashion.

20  
21 The common radiology characteristic in our cases was ground glass opacities, present in all  
22 cases except #7. Since median age at HRCT was 9 months except for case #7 (26 years), age  
23 may be a determining factor, although we cannot exclude mutation severity or other factors.  
24 In the literature, chest radiograms and/or HRCT show diffuse ground-glass opacities in

1 neonates<sup>15</sup>, whereas in older infants and children, interstitial thickening associated with  
2 lung hyperinflation, intraparenchymal/supleural cysts, honeycombing, subpleural nodules  
3 <sup>8,37</sup>, or bronchiectasis <sup>14</sup> are more prominent. These patterns are not different from those  
4 observed in other genetic surfactant deficiencies <sup>38</sup>. Infiltrates and air leaks are frequent  
5 complication in acute exacerbations <sup>17</sup>. Focal or diffuse reticulonodular patterns,  
6 centrolobular and subpleural nodules and cystic lesions are described in adults <sup>29,30</sup>.

7  
8 We did not observe specific differences in lung histology between our cases, in whom lung  
9 biopsy was obtained at a median age of 6 months. We observed a combination of DIP with  
10 features of PAP, a pattern common to most genetic surfactant deficiencies in infants <sup>1</sup>. In the  
11 literature, older children and adults with SP-C mutations display patchy fibrotic lesions of  
12 usual interstitial pneumonia or diffuse non-specific interstitial pneumonia, in combination  
13 with nodular septa thickening and clustered cystic lesions <sup>29,30</sup>, suggesting lung tissue  
14 morphology is more age-specific rather than disease-specific.

15  
16 However by TEM we observed significant anomalies in LB number and appearance in all  
17 cases examined, indicating altered surfactant composition/ structure. These alterations are  
18 distinct from those observed in SP-B or ABCA3 deficiency <sup>3,6</sup> and appear specific in both our  
19 observations and the literature <sup>15,28</sup>. In SP-C deficient mice, LBs and extracellular surfactant  
20 are similar to controls <sup>39</sup>, suggesting that the human disease is not primarily caused by SP-C  
21 haploinsufficiency itself. However, even though human SP-C mutations are mono-allelic and  
22 both the wild type and the mutated alleles are transcribed, mature SP-C peptide is not (or  
23 barely) detected in lung tissue and bronchoalveolar lavage fluid <sup>17,40</sup>. Overall, these findings  
24 and data suggest that surfactant deficiency, due to a toxic gain-of-function mechanism

1 affecting lamellar body formation and surfactant synthesis, may contribute in part to the  
2 pathogenesis in human. In addition, in the 3 carriers of linker domain mutations in whom  
3 lung biopsy was performed (cases #1-3), we observed numerous large endosomes. Similar,  
4 albeit smaller, vesicles were observed in the other linker mutant (case #5), although the  
5 material was obtained by BAL and processed differently, hence may not be strictly  
6 comparable. Although very few TEM data have been published on human subjects with SP-C  
7 mutations, similar vesicles in one linker mutation case were shown by immunogold staining  
8 to co-localize with proSP-C, suggesting a trafficking defect <sup>15</sup>. Conversely in the single  
9 BRICHOS domain mutation carrier analyzed by TEM (case #6), we found hyperplastic ER  
10 and perinuclear electron-dense aggregates, which, if confirmed in other cases, could reflect  
11 misfolded protein-related cell toxicity <sup>41</sup>.

12  
13 Although bi-allelic mutations have been reported exceptionally <sup>13,20</sup>, loss of function is not a  
14 prominent mechanism in human SP-C deficiency, which is typically caused by mono-allelic  
15 mutations. SP-C null mutant mice are viable, showing that SP-C is not critical for survival.  
16 Hence different pathophysiological processes, depending on distinct types of gene defects,  
17 are involved in human SP-C mutation-associated lung disease and, likely, account for this  
18 phenotypic heterogeneity.

19 Mutations in the linker (non-BRICHOS) sequence (aa59-89) of the C-terminal peptide exert  
20 their pathogenic effect by inducing aberrant intracellular trafficking of proSP-C, which  
21 eludes cleavage and accumulates in endosomes and MVBs <sup>25</sup>. In cases #1-3, we observed  
22 large proSP-C -positive vesicles in type II cell cytoplasm by immunohistochemistry.  
23 Confocal immunofluorescence microscopy in one case (#1) showed partial co-localization  
24 of proSP-C and LAMP-3, a marker expressed in MVBs and LBs, confirming abnormal

1 accumulation of the uncleaved pro-peptide in these organelles. Overall, our observations in  
2 human subjects are compatible with the model proSP-C misprocessing, accumulation in  
3 MVBs, aberrant secretion and reuptake in the endosomal/lysosomal pathway derived from  
4 animal and in-vitro studies <sup>24,25</sup> but are less clear-cut and may be of limited clinical use,  
5 likely because of the coexistence of a wild type and a mutated *SFTPC* allele, both expressed  
6 to a certain degree and resulting in a mixed phenotype.

7 The majority of mutations reported in human affect the highly conserved BRICHOS domain  
8 (aa90-197), common to proSP-C and other proteins associated with dementia, and bone and  
9 gastric cancer. The mature SP-C peptide is highly hydrophobic and tends to form  $\beta$ -sheets  
10 aggregates and amyloid fibrils in vitro <sup>13,42</sup>. In fact, overexpression of the mature SP-C  
11 peptide in transgenic mice leads to neonatal lethality<sup>42</sup>, The BRICHOS domain functions as a  
12 chaperone, preventing aggregation and amyloid formation. In-vitro mutagenesis and  
13 transgenic mice studies demonstrated that BRICHOS domain mutations lead to SP-C  
14 misfolding, accumulation in the ER, amyloid formation, disruption of the ubiquitin-  
15 proteasome system, activation of the apoptosis cascade, and type II cell death. <sup>13,24,33,43</sup>. The  
16 proSP-C perinuclear expression pattern observed in case #6 may reflect peptide  
17 segregation and aggregation in the ER, but confirmatory confocal immunofluorescence  
18 studies with a specific ER marker could not be performed in this case due to the lack of  
19 frozen tissue, and more cases would be necessary to confirm these speculations. We could  
20 demonstrate the presence of amyloid in the interstitium in one of the four subjects with  
21 linker domain mutations, further supporting this mechanism. However, amyloid was also  
22 detected in patient #1, suggesting that protein misfolding occurs to some degree in linker  
23 domain mutants.

24 However, these conclusion should be balanced by the limited number of cases with lung

1 tissue available, and by the fact that, as in most pathology studies based on human cases, it  
2 is difficult to establish which findings are part of the underlying disease process per se,  
3 which are a response to the underlying mechanism of disease, and which might be the  
4 result of interventions (such as mechanical ventilation) or duration or severity of disease.

5  
6 The 5 subjects with linker domain mutations carried known pathogenic variants, 4 of which  
7 were p.(Ile73Thr). Although linker domain mutations have been reported to have a less  
8 severe clinical expression than BRICHOS mutation in some series <sup>7,17</sup>, our own data and the  
9 literature do not necessarily support this concept. We found three BRICHOS domain rare  
10 variants in our series. No other *SFTPB*, *ABCA3* or *NKX2.1* mutations were present in these  
11 subjects. The p.(Val102Met) variant (case #6) is predicted to be deleterious in silico by both  
12 algorithms and is mostly conserved among species; its pathogenic role is supported by  
13 histologic and ultrastructural findings including amyloid deposits <sup>13</sup>; it was also reported in  
14 another patient with neonatal-onset respiratory failure [16, online supplement]. The  
15 p.(Phe173His) variant (case #8), unreported so far, appears damaging on PolyPhen-2 but  
16 not on SIFT, and is also less conserved among species (table 2), making its pathogenicity  
17 questionable. The more severe clinical course in the proband compared to the non-mutated  
18 siblings supports mutation pathogenicity, but prematurity (as a potential cause of lung  
19 disease) and the favorable outcome may suggest it as a benign variant. The role of the  
20 p.(Arg155Pro) variant (case #7) is also less clear, as this missense mutation shows a low  
21 damaging probability and has been reported in three subjects of European descent (0.04%)  
22 in the NHBLI Exome sequencing project. Since no lung tissue was available for phenotype  
23 correlation and the parents did not consent for genetic testing, we cannot affirm that this  
24 variant is responsible for the subject's lung disease. The relevance of the associated

1 synonymous ABCA3 mutation observed in patient #1 is uncertain. Compound genotypes  
2 associating I73T and an ABCA3 mutation have been reported in infants with pDLD <sup>19</sup> and in  
3 adults with late-onset ILD, suggesting that a mono-allelic ABCA3 mutation may act as  
4 disease modifier in SP-C defects <sup>21</sup>.

5

## 6 Conclusion

7 This case series illustrates the vast array of symptoms and outcomes associated with SP-C  
8 deficiency, and shows correlations between known and new genotypes and lung  
9 ultrastructure, supporting the importance of lung biopsy including TEM analysis for  
10 accurate diagnosis. Broncho-alveolar lavage may represent an alternative, less invasive  
11 diagnostic procedure than lung biopsy if validated in future studies. Since this clinical  
12 variability is only partially supported by molecular and genetic mechanisms, future  
13 research should focus on determining individual genotypes through genomic approaches, in  
14 order to expand the understanding of genetic-clinical correlations and interactions with  
15 other surfactant-related genes.

16

17 This study was limited by the number of cases and by the lack of mutagenesis studies  
18 susceptible to better establish disease mechanism correlations. As for any rare disorder,  
19 only large collaborative initiatives may yield the sufficient power of validating new  
20 diagnostic and therapeutic approaches.

21

## 22 Acknowledgements

23 We are grateful to Dr. Paola Carrera, Clinical Molecular Biology Laboratory, Università Vita-  
24 Salute San Raffele, Milan, Italy for *SFTPC* sequencing in patient #5. This publication was



1 supported by an unrestricted grant by the Chiesi Foundation, Parma, Italy

2

3 Conflict of interest statement.

4 The authors declare that there is no conflict of interests regarding the publication of this  
5 paper. The studies were conducted in compliance with the hospitals internal review boards  
6 and research committees.

7 Supplementary information is available at European Journal of Human Genetics's website  
8 (<http://www.nature.com/ejhg>).

## 1 References

- 2 1. Deutsch GH, Young LR, Deterding RR *et al*: Diffuse lung disease in young children:  
3 application of a novel classification scheme. *Am J Respir Crit Care Med* 2007; **176**:  
4 1120-1128.  
5
- 6 2. Somaschini M, Noguee LM, Sassi I *et al*: Unexplained neonatal respiratory distress due  
7 to congenital surfactant deficiency. *J Pediatr* 2007; **150**: 649-653, 653 e641.  
8
- 9 3. Shulenin S, Noguee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene  
10 mutations in newborns with fatal surfactant deficiency. *N Engl J Med* 2004; **350**:  
11 1296-1303.  
12
- 13 4. Blanco O, Perez-Gil J: Biochemical and pharmacological differences between  
14 preparations of exogenous natural surfactant used to treat Respiratory Distress  
15 Syndrome: role of the different components in an efficient pulmonary surfactant. *Eur*  
16 *J Pharmacol* 2007; **568**: 1-15.  
17
- 18 5. Brasch F, Ten Brinke A, Johnen G *et al*: Involvement of cathepsin H in the processing  
19 of the hydrophobic surfactant-associated protein C in type II pneumocytes. *Am J*  
20 *Respir Cell Mol Biol* 2002; **26**: 659-670.  
21
- 22 6. Bullard JE, Wert SE, Whitsett JA, Dean M, Noguee LM: ABCA3 mutations associated  
23 with pediatric interstitial lung disease. *Am J Respir Crit Care Med* 2005; **172**: 1026-  
24 1031.  
25
- 26 7. Guillot L, Epaud R, Thouvenin G *et al*: New surfactant protein C gene mutations  
27 associated with diffuse lung disease. *J Med Genet* 2009; **46**: 490-494.  
28
- 29 8. Abou Taam R, Jaubert F, Emond S *et al*: Familial interstitial disease with I73T  
30 mutation: A mid- and long-term study. *Pediatr Pulmonol* 2009; **44**: 167-175.  
31
- 32 9. Thomas AQ, Lane K, Phillips J, 3rd *et al*: Heterozygosity for a surfactant protein C  
33 gene mutation associated with usual interstitial pneumonitis and cellular nonspecific  
34 interstitial pneumonitis in one kindred. *Am J Respir Crit Care Med* 2002; **165**: 1322-  
35 1328.  
36
- 37 10. McBee AD, Wegner DJ, Carlson CS *et al*: Recombination as a mechanism for sporadic  
38 mutation in the surfactant protein-C gene. *Pediatr Pulmonol* 2008; **43**: 443-450.  
39
- 40 11. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC: SIFT web server: predicting  
41 effects of amino acid substitutions on proteins. *Nucleic acids research* 2012; **40**:  
42 W452-457.  
43
- 44 12. Vorbroker DK, Profitt SA, Noguee LM, Whitsett JA: Aberrant processing of surfactant  
45 protein C in hereditary SP-B deficiency. *Am J Physiol* 1995; **268**: L647-656.  
46

- 1 13. Willander H, Askarieh G, Landreh M *et al*: High-resolution structure of a BRICHOS  
2 domain and its implications for anti-amyloid chaperone activity on lung surfactant  
3 protein C. *Proc Natl Acad Sci U S A* 2012; **109**: 2325-2329.  
4
- 5 14. Salerno T, Peca D, Rossi FP, Menchini L, Danhaive O, Cutrera R: Bronchiectasis And  
6 Severe Respiratory Insufficiency Associated With A New Surfactant Protein C  
7 Mutation. *Acta Paediatr* 2012.  
8
- 9 15. Stevens PA, Pettenazzo A, Brasch F *et al*: Nonspecific interstitial pneumonia, alveolar  
10 proteinosis, and abnormal proprotein trafficking resulting from a spontaneous  
11 mutation in the surfactant protein C gene. *Pediatr Res* 2005; **57**: 89-98.  
12
- 13 16. Nogee LM, Dunbar AE, 3rd, Wert S, Askin F, Hamvas A, Whitsett JA: Mutations in the  
14 surfactant protein C gene associated with interstitial lung disease. *Chest* 2002; **121**:  
15 20S-21S.  
16
- 17 17. Thouvenin G, Abou Taam R, Flamein F *et al*: Characteristics of disorders associated  
18 with genetic mutations of surfactant protein C. *Arch Dis Child* 2010; **95**: 449-454.  
19
- 20 18. Brasch F, Griese M, Tredano M *et al*: Interstitial lung disease in a baby with a de novo  
21 mutation in the SFTPC gene. *Eur Respir J* 2004; **24**: 30-39.  
22
- 23 19. Bullard JE, Nogee LM: Heterozygosity for ABCA3 mutations modifies the severity of  
24 lung disease associated with a surfactant protein C gene (SFTPC) mutation. *Pediatr*  
25 *Res* 2007; **62**: 176-179.  
26
- 27 20. Cameron HS, Somaschini M, Carrera P *et al*: A common mutation in the surfactant  
28 protein C gene associated with lung disease. *J Pediatr* 2005; **146**: 370-375.  
29
- 30 21. Crossno PF, Polosukhin VV, Blackwell TS *et al*: Identification of early interstitial lung  
31 disease in an individual with genetic variations in ABCA3 and SFTPC. *Chest* 2010;  
32 **137**: 969-973.  
33
- 34 22. Lawson WE, Grant SW, Ambrosini V *et al*: Genetic mutations in surfactant protein C  
35 are a rare cause of sporadic cases of IPF. *Thorax* 2004; **59**: 977-980.  
36
- 37 23. Percopo S, Cameron HS, Nogee LM, Pettinato G, Montella S, Santamaria F: Variable  
38 phenotype associated with SP-C gene mutations: fatal case with the I73T mutation.  
39 *Eur Respir J* 2004; **24**: 1072-1073.  
40
- 41 24. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF: A surfactant protein C  
42 precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress,  
43 proteasome dysfunction, and caspase 3 activation. *Am J Respir Cell Mol Biol* 2005; **32**:  
44 521-530.  
45
- 46 25. Beers MF, Hawkins A, Maguire JA *et al*: A nonaggregating surfactant protein C mutant  
47 is misdirected to early endosomes and disrupts phospholipid recycling. *Traffic* 2011;  
48 **12**: 1196-1210.

- 1  
2 26. Nathan N, Taam RA, Epaud R *et al*: A national internet-linked based database for  
3 pediatric interstitial lung diseases: the French network. *Orphanet J Rare Dis* 2012; **7**:  
4 40.  
5  
6 27. Soraisham AS, Tierney AJ, Amin HJ: Neonatal respiratory failure associated with  
7 mutation in the surfactant protein C gene. *J Perinatol* 2006; **26**: 67-70.  
8  
9 28. Hamvas A, Noguee LM, White FV *et al*: Progressive lung disease and surfactant  
10 dysfunction with a deletion in surfactant protein C gene. *Am J Respir Cell Mol Biol*  
11 2004; **30**: 771-776.  
12  
13 29. van Moorsel CH, van Oosterhout MF, Barlo NP *et al*: Surfactant protein C mutations  
14 are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch  
15 cohort. *Am J Respir Crit Care Med* 2010; **182**: 1419-1425.  
16  
17 30. Ono S, Tanaka T, Ishida M *et al*: Surfactant protein C G100S mutation causes familial  
18 pulmonary fibrosis in Japanese kindred. *Eur Respir J* 2011; **38**: 861-869.  
19  
20 31. Ramet M, Haataja R, Marttila R, Floros J, Hallman M: Association between the  
21 surfactant protein A (SP-A) gene locus and respiratory-distress syndrome in the  
22 Finnish population. *Am J Hum Genet* 2000; **66**: 1569-1579.  
23  
24 32. Giannoni E, Sawa T, Allen L, Wiener-Kronish J, Hawgood S: Surfactant proteins A and  
25 D enhance pulmonary clearance of *Pseudomonas aeruginosa*. *Am J Respir Cell Mol*  
26 *Biol* 2006; **34**: 704-710.  
27  
28 33. Zarbock R, Woischnik M, Sparr C *et al*: The surfactant protein C mutation A116D  
29 alters cellular processing, stress tolerance, surfactant lipid composition, and immune  
30 cell activation. *BMC Pulm Med* 2012; **12**: 15.  
31  
32 34. Maguire JA, Mulugeta S, Beers MF: Endoplasmic reticulum stress induced by  
33 surfactant protein C BRICHOS mutants promotes proinflammatory signaling by  
34 epithelial cells. *Am J Respir Cell Mol Biol* 2011; **44**: 404-414.  
35  
36 35. Tucker S, Ahl M, Bush A, Westaway D, Huang X, Rogers JT: Pilot study of the reducing  
37 effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's  
38 APP 5' untranslated region. *Current Alzheimer research* 2005; **2**: 249-254.  
39  
40 36. Beers MF: Inhibition of cellular processing of surfactant protein C by drugs affecting  
41 intracellular pH gradients. *J Biol Chem* 1996; **271**: 14361-14370.  
42  
43 37. Tredano M, Griese M, Brasch F *et al*: Mutation of SFTPC in infantile pulmonary  
44 alveolar proteinosis with or without fibrosing lung disease. *Am J Med Genet A* 2004;  
45 **126A**: 18-26.  
46  
47 38. Young LR, Noguee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH: Usual interstitial  
48 pneumonia in an adolescent with ABCA3 mutations. *Chest* 2008; **134**: 192-195.

- 1  
2 39. Glasser SW, Burhans MS, Korfhagen TR *et al*: Altered stability of pulmonary  
3 surfactant in SP-C-deficient mice. *Proc Natl Acad Sci U S A* 2001; **98**: 6366-6371.  
4  
5 40. Nogee LM, Dunbar AE, 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in  
6 the surfactant protein C gene associated with familial interstitial lung disease. *N Engl*  
7 *J Med* 2001; **344**: 573-579.  
8  
9 41. Mulugeta S, Maguire JA, Newitt JL, Russo SJ, Kotorashvili A, Beers MF: Misfolded  
10 BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-  
11 related mechanisms. *Am J Physiol Lung Cell Mol Physiol* 2007; **293**: L720-729.  
12  
13 42. Conkright JJ, Na CL, Weaver TE: Overexpression of surfactant protein-C mature  
14 peptide causes neonatal lethality in transgenic mice. *Am J Respir Cell Mol Biol* 2002;  
15 **26**: 85-90.  
16  
17 43. Bridges JP, Wert SE, Nogee LM, Weaver TE: Expression of a human surfactant protein  
18 C mutation associated with interstitial lung disease disrupts lung development in  
19 transgenic mice. *J Biol Chem* 2003; **278**: 52739-52746.  
20  
21  
22

1 Titles and legends to figures

2 **Figure 1: Lung tissue morphology and surfactant protein immunohistochemistry.**

3 Immunohistochemistry staining for SP-B (columns 1 and 2, 10x and 40x magnification  
4 respectively) and pro-SP-C (columns 3 and 4) in a 3-month-old control (row 1), three  
5 linker domain mutants (row 2-4) and one BRICHOS SP-C mutant (row 5). AEC2  
6 hyperplasia is present in all four cases compared to control. In control, proSP-C is  
7 expressed in the cytoplasm surrounding clearer-appearing lamellar bodies (row 1,  
8 insert, arrows). In cases #1-3, proSP-C is diffusely overexpressed in the cytoplasm with  
9 a granular pattern (row 3, insert, arrows). In case #6, proSP-C is overexpressed with a  
10 perinuclear pattern and some scattered aggregates (row 5, insert, arrows).  
11 Counterstaining with hematoxylin-eosin.

12

13 **Figure 2: Amyloid detection.** A. Congo red staining of case #6 lung specimen showing

14 a small Congo-positive deposit in the interstitium, near cholesterol clefts (arrow). B.

15 Same specimen viewed under polarized light optical microscopy, the deposit showing

16 green birefringence indicating amyloid (arrow).

17

18 **Figure 3: Type II cell ultrastructure.** Type II cell sections in a control subject, four

19 linker domain mutation carriers (cases #1-3 and #5) and one BRICHOS mutation carrier

20 (#6). Tissue was obtained by autopsy for control and live biopsy for cases #1-3 and 6;

21 cells were obtained by bronchoalveolar lavage for case #5. In control, numerous mature

22 lamellar bodies with pseudomyelin are present (arrow). Cases #1-4 show numerous,

23 large coalescing endosomes with scarce amorphous content (arrow), some lysosomes,

24 and few multivesicular bodies (inserts). Case #6 shows hypertrophic endoplasmic

- 1 reticulum (\*) compared to control, some cytoplasmic electron-dense deposits (block
- 2 arrows) and several multivesicular bodies (arrows) with disorganized phospholipid
- 3 membranes and amorphous content (insert).

Table 1. Clinical course and phenotype.

Case	Sex, BW, GA, family history	Presentation and clinical course	HRCT imaging	Treatment and outcome	ProSP-C expression and amyloid staining	Ultrastructure
1	F; term; 3,30 Kg Parents and one sibling healthy	Dyspnea and failure to thrive at 1 m PICU from 3 m Lung biopsy 3 m	3 m: ground glass opacities, upper lobes cysts, upper lobar emphysema, PTX	O <sub>2</sub> from 1 m, MV from 3 m PS + HCQ from 3 m Death 6 m	AEC2 hyperplasia Granular proSP-C pattern with diffuse large aggregates Several amyloid deposits	Many large endosomes Very rare LBs with abnormal PL structure
2	M; term; 3,70 Kg Parents healthy, no siblings	Multiple bronchiolitis episodes 3-12 m Hypoxemia from 14 m PICU from 14 m Lung biopsy 18 m	14 m: ground glass opacities, multifocal interstitial infiltrates	O <sub>2</sub> from 14 m, MV from 15m, tracheostomy 16 m PS + HCQ from 15 m Death 19 m	Marked AEC2 hyperplasia Granular proSP-C pattern with diffuse large aggregates No amyloid detected	Many large endosomes with some PL content Very rare immature LBs and MVBs
3	M; term; 3.00 Kg Healthy parents and sister	Bronchiolitis 5 m PICU 9-13 month for respiratory failure, recurrent PTX Lung biopsy 15 m	9 m: ground glass opacities, multiple cysts	O <sub>2</sub> from 11m, MV 9-11 m PS + HCQ from 13 m Alive on O <sub>2</sub> at 48 m Listed for transplant	AEC2 hyperplasia Granular proSP-C pattern with diffuse large aggregates No amyloid detected	Many large endosomes with PL content Very rare LBs
4	F; term; 3.30 Kg 1 sibling, fatal respiratory failure 16 m	Chronic cough and dyspnea since 7 m PICU 18-19 m for hypoxemia and dyspnea	10 m: Diffuse ground glass opacities, honeycombing, multiple subpleural nodules.	O <sub>2</sub> 18-21 m HCQ from 21 m Alive on room air at 30 m	n/a	n/a
5	M, Term, 2.990 Kg Parents healthy, no siblings	Chronic cough, failure to thrive since 9 m Hospitalized 13-14 m for dyspnea and hypoxemia	13 m: Diffuse ground-glass opacities	O <sub>2</sub> 13-19 m Steroids for 5 m at 13 m AZM 18 m, HCQ from 13 m Alive on room air at 21 m	n/a	(tracheal aspirate) Some large endosomes with PL content Rare MVBs
6	F; term; 3.03 Kg Parents healthy, no siblings	Hospitalized for bronchiolitis at 6m Hospitalized 11-15 m for hypoxemia and PTX, lung biopsy at 14 m	6 m: diffuse ground glass opacities, basal emphysema	O <sub>2</sub> since 13 m, MV 6-7 m PS 11-12 m HCQ from 16 m Alive on O <sub>2</sub> at 24 m	Marked AEC2 hyperplasia Some granular proSP-C pattern plus perinuclear aggregates Rare amyloid deposits	Numerous mitochondria, lysosomes and electron-dense deposits Several normal LBs Several MVBs



7	F; term; 3.00 Kg Parents healthy, no siblings	Pneumonia at 1 y, Several hospitalizations for LRTI in childhood; Severe failure to thrive Hypoxemia at 26 y	26 y: mild interstitial lung disease, diffuse tubular and varicose bronchiectasis, basal infiltrates	Intermittently on O <sub>2</sub> , never ventilated Multiple antibiotic and PS courses, bronchodilators Alive at 28 y on O <sub>2</sub>	n/a	n/a
8	M; 28w; 0.90 Kg Parents healthy, two triplet siblings with no CLD	Severe RDS at birth, 2 doses of surfactant, MV until 4 w	2 m: diffuse ground-glass opacities, overexpansion, bronchial markings	O <sub>2</sub> 2-4m, MV 1 m Steroids 1 m Alive on rom air at 14 m	n/a	n/a

**Abbreviations:**

M: male; F: female; w: weeks; m: months; y: years; RDS: respiratory distress syndrome; CLD: chronic lung disease; m: month; Y: year; PICU: pediatric intensive care unit; PTX: pneumothorax; LRTI: lower respiratory tract infection; MV: mechanical ventilation; XR: radiogram; CT: computed tomography scan; ILD: interstitial lung disease; O<sub>2</sub>: supplemental oxygen; PS: pulse steroids; HCQ: hydroxychloroquine; AZM: azithromycin.

Table 2. SFPTC Variants Found in Individuals

Case	Variant <sup>a</sup>	Inheritance	dbSNP/LOVD	Annotation	SIFT/Polyphen2	1000G/ESP <sup>b</sup>	Species conservation
1	<b>c.196G&gt;A p.(E66K)</b>	Paternal	rs121917836 0000053109	Pathogenic <sup>c</sup>	Tolerated, score 0.18/probably damaging, 0.99	nd/nd <sup>d</sup>	Highly conserved
2	<b>c.218T&gt;C p.(I73T)</b>	Paternal	rs121917834 0000053110	Pathogenic <sup>e</sup>	Damaging, score 0/possibly damaging, 0.85	nd/nd	Mostly conserved
3	<b>c.218T&gt;C p.(I73T)</b>	Paternal	rs121917834 0000053110	Pathogenic	Damaging, score 0/possibly damaging, 0.85	nd/nd	Mostly conserved
4	<b>c.218T&gt;C p.(I73T)</b>	Unknown; sibling died of RDS	rs121917834 0000053110	Pathogenic	Damaging, score 0/possibly damaging, 0.85	nd/nd	Mostly conserved
5	<b>c.218T&gt;C p.(I73T)</b>	Maternal	rs121917834 0000053110	Pathogenic	Damaging, score 0/possibly damaging, 0.85	nd/nd	Mostly conserved
6	<b>c.304G&gt;A p.(V102M)</b>	Sporadic	<sup>g</sup> See footnote 0000053108	nd	Tolerated, score 0.08/probably damaging, 1.00	nd/nd	Highly conserved
7	c.463G>C p.(A155P)	Unknown	rs202145169 <sup>h</sup> 0000053106	nd	Tolerated, score 0.28/Benign, 0.004	nd/0.0359 EA <sup>i</sup>	Variable
8	c.518C>A p.(P173H)	Sporadic 2 siblings negative	Not reported 0000053104	nd	Tolerated, score 0.08/possibly damaging, 0.94	nd/nd	Variable

<sup>a</sup>Column 2: in bold, established or probable disease-causing variants; in light, variants of uncertain significance.

<sup>b</sup>1000 Genomes Project phase1, NHBLI Exome sequencing project

<sup>c</sup>OMIM, <http://www.ncbi.nlm.nih.gov/pubmed/15557112>

<sup>d</sup>nd=no data, not present

<sup>e</sup>OMIM, <http://www.ncbi.nlm.nih.gov/pubmed/11991887>, <http://www.ncbi.nlm.nih.gov/pubmed/15293602>,





















<http://www.ncbi.nlm.nih.gov/pubmed/19443464>



<sup>f</sup>synonymous variant






<sup>g</sup>Willander et al. *Proc Natl Acad Sci U S A*, vol. 109, no. 7, pp. 2325-2329, 2012, online supplement.

<sup>h</sup>Reported in three European Americans in ESP, heterozygous

<sup>i</sup>Minor allele frequency in European Americans in ESP







## **Supplementary material**

Supplemental data and methods

Figure S1 and S2

### Clinical and ultrastructural spectrum of diffuse lung disease associated with surfactant protein C mutations

Donatella Peca<sup>1</sup>, Renata Boldrini<sup>2</sup>, Janne Johannson<sup>3</sup>, Joseph T Shieh<sup>4</sup>, Arianna Citti<sup>2</sup>, Stefania Petrini<sup>1</sup>, Teresa Salerno<sup>5</sup>, Salvatore Cazzato<sup>6</sup>, Raffaele Testa<sup>7</sup>, Francesco Messina<sup>8</sup>, Alfredo Onofri<sup>9</sup>, Giovanna Cenacchi<sup>10</sup>, Per Westermark<sup>11</sup>, Paola Cogo<sup>12</sup>, Renato Cutrera<sup>5</sup> and Olivier Danhaive<sup>13,4</sup>.

#### Corresponding author:

Olivier Danhaive, M.D.

Department of Pediatrics, University of California San Francisco

San Francisco General Hospital

1001 Potrero Avenue, Mailstop 6E, San Francisco, CA 94110

Telephone: +1-415-206-8361 - Fax: +1-415-206-3686

Email: danhaiveo@peds.ucsf.edu

#### Running title:

Histopathology and ultrastructural features of SP-C mutations

#### Authors affiliations:

<sup>1</sup>Research core laboratories, Bambino Gesù Children's Hospital, Rome, Italy; <sup>2</sup>Division of Anatomopathology, Bambino Gesù Children's Hospital, Rome, Italy; <sup>3</sup>Department of Neurobiology, Care sciences and Society, Karolinska Institutet, Huddinge, Sweden; <sup>4</sup>Department of Pediatrics, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA; <sup>5</sup>Department of Pediatrics, Bambino Gesù Children's Hospital, Rome, Italy; <sup>6</sup>Division of Pediatric Pulmonology, S. Orsola-Malpighi University Hospital, Bologna, Italy; <sup>7</sup>Division of Pediatric intensive Care, Santobono Hospital, Naples, Italy; <sup>8</sup>Division of Neonatology, Villa Betania Hospital, Naples, Italy; <sup>9</sup>Division of Pediatric Intensive Care, Bambino Gesù Children's Hospital, Rome, Italy; <sup>10</sup>Division of Clinical Pathology, S. Orsola-Malpighi University Hospital, Bologna, Italy; <sup>11</sup>Department of Immunology, Genetics and Pathology, Uppsala University, Sweden; <sup>12</sup>Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy; <sup>13</sup>Department of Medical and Surgical Neonatology, Bambino Gesù Children's Hospital, Rome, Italy.

### Diffuse lung disease cohort characteristics

From January 1<sup>st</sup> 2005 to June 30<sup>th</sup> 2012, 121 children 0-18 year-old were evaluated for diffuse lung disease. After exclusion of active bacterial or viral infection including tuberculosis and aspergillosis, immune deficiencies, primary ciliary dyskinesia, chronic tracheal aspiration, congenital heart disease with left-to-right shunt, cystic fibrosis and other causes, genetic testing was performed, with specific gene selection based on age of onset and clinical presentation. For neonates with fatal hypoxic respiratory failure, *SFTPB* and *ABCA3* were tested first; for those with severe pulmonary hypertension suggesting alveolar capillary dysplasia, *FOXF1* (NM\_001451.2) was added. In later-onset cases *SFTPC* was tested primarily, then *ABCA3* when the former was negative. *NKX2.1* (NM\_001079668.2) was primarily tested in cases with associated hypothyroidism or movement disorder. Additional testing was performed in cases that remained unexplained. The number of patients tested for these genes and the relative proportion of mutants detected is indicated in the following table:

<u>Total (n)</u>	121		
<u>cases tested (n)</u>		<u>bi-allelic mutations</u>	<u>mono-allelic mutations</u>
SFTPB	49	0	3 (6%)
SFTPC	88	0	8 (9%)
ABCA3	74	10 (14%)	4 (5%)
NKX2.1	16	0	2 (12%)
FOXF1	15	0	2 (13%)

Other congenital diseases were found in six cases: pulmonary interstitial glycogenosis in two, cytochrome oxidase deficiency in one, Niemann-Pick disease type B in one, alveolar capillary dysplasia without *FOXF1* mutation in two.

Confocal microscopy methods: studies were performed in one patient (case #1), in whom frozen lung tissue was available, and in an age-matched control subject. Serial lung cryosections (5 µm) were air-dried and incubated with polyclonal anti proSP-C (Millipore, Billerica, MA) diluted in 0,1 M phosphate buffered saline (PBS, pH 7.4) containing 1% bovine serum albumine (BSA). After PBS washes, slides were incubated with goat anti rabbit Alexa Fluor 488-conjugated immunoglobulin (Molecular Probes, Eugene, OR). Double staining was performed using one of the following mouse monoclonal antibodies: anti SP-B (Labvision, Fremont, CA), protein disulphide isomerase (PDI, Molecular Probes, Eugene, OR), and LAMP3 (Santa Cruz Biotechnology, Santa Cruz, CA) and revealed with goat anti-mouse IgG conjugated with Alexa Fluor 555 (Molecular Probes, Eugene, OR). Negative controls were performed using PBS/BSA 1% without the primary antibody. Slides were mounted in 50% glycerol in PBS and examined using an Olympus IX81 inverted microscope equipped with epifluorescence optics; image acquisition and co-localization analysis were performed using an Olympus fluoview FV1000 confocal microscope equipped with FV10-ASW version 2.0 software, Multi Ar (458-488 and 514 nm) and 2X He/Ne (543 and 633 nm) lasers with 60X oil immersion objective (Olympus, Center Valley, PA). Images were processed using Adobe Photoshop 9.0 software (Adobe, San Jose, CA).



### Figure S1 legend

Confocal microscopy analysis after immunofluorescent labeling of proSP-C in green, and either protein disulphide isomerase – an endoplasmic reticulum marker - (PDI) or lysosome-associated membrane protein 3 (LAMP3), a multivesicular and lamellar body marker, both in red; co-expression pattern shown in merged images (column 3). In control (line 1 and 2), proSP-C shows limited co-localization with PDI and LAMP-3. In contrast, in the p.(Glu66Lys) mutation carrier (case #1) limited proSP-C co-localization with PDI is observed, but there is a stronger proSP-C colocalization with LAMP3.

### Figure S2 legend

Transmission electron microscopy of lung tissue in patient #1, showing an alveolar epithelial type 2 cell secreting large vesicles with heterogeneous content in the alveolar lumen.

Figure S1




Figure S2

